Zhaozhen Wu
Overview
Explore the profile of Zhaozhen Wu including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
18
Citations
351
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Han F, Wu Z, Chen J, Liu M, Hu Y
Cancer Med
. 2023 Nov;
12(23):21129-21137.
PMID: 37990780
Objective: To compare the efficacy and safety of first-line anti-PD-1 combined with chemotherapy versus chemotherapy alone in patients with advanced urothelial carcinoma (UC). Method: Patients with advanced UC who received...
2.
Wu Z, Zhang S, Li L, Huang Z, Huang D, Hu Y
Front Oncol
. 2022 Nov;
12:887383.
PMID: 36387171
Background: Immune checkpoint inhibitors (ICIs) targeting programmed cell death protein 1 (PD-1) have been widely used in treating different malignancies. Several studies have reported that the gut microbiota modulates the...
3.
Chen S, Zhang Z, Zheng X, Tao H, Zhang S, Ma J, et al.
Front Oncol
. 2021 May;
11:562315.
PMID: 33937012
Background: Immune checkpoint inhibitors targeting the PD-1/PD-L1 pathway have demonstrated promise in treating a variety of advanced cancers; however, little is known regarding their efficacy under various clinical situations, including...
4.
Wu Z, Tao H, Zhang S, Wang X, Ma J, Li R, et al.
Cancer Immunol Immunother
. 2021 Mar;
70(10):2971-2980.
PMID: 33740125
Background: Rationale exists for combining immune checkpoint inhibitors and PARP inhibitors (PARPi), and results of clinical trials in ovarian cancer are promising, but data in other cancers are limited. Method:...
5.
Wu Z, Cui P, Tao H, Zhang S, Ma J, Liu Z, et al.
Clin Med Insights Oncol
. 2021 Mar;
15:1179554921996288.
PMID: 33737855
Poly (ADP-ribose) polymerase (PARP) inhibitors have demonstrated great promise for treating cancers with homologous recombination (HR) defects, such as germline BRCA1/2 mutation. Further studies suggest that PARP inhibitors (PARPi) can...
6.
Chen S, Huang Z, Jia W, Tao H, Zhang S, Ma J, et al.
J Hepatocell Carcinoma
. 2020 Nov;
7:289-299.
PMID: 33173757
Purpose: At present, there are no validated biomarkers that can predict whether patients with advanced hepatocellular carcinoma (aHCC) are likely to benefit from anti-PD-1 therapy. We aimed to determine whether...
7.
Huang D, Cui P, Huang Z, Wu Z, Tao H, Zhang S, et al.
J Cancer Res Clin Oncol
. 2020 Sep;
147(3):881-891.
PMID: 32909095
Purpose: Anti-programmed cell death protein 1 or its ligand (anti-PD-1/L1) monotherapy has become the standard second-line treatment in advanced lung adenocarcinoma. However, the strategy treatment of anti-PD-1/L1 plus anti-angiogenesis therapy...
8.
Cui P, Li R, Huang Z, Wu Z, Tao H, Zhang S, et al.
Sci Rep
. 2020 Aug;
10(1):13160.
PMID: 32753702
The efficacies of pembrolizumab and nivolumab have never been directly compared in a real-world study. Therefore, we sought to retrospectively evaluate the objective response rate (ORR) and the progression-free survival...
9.
Cui P, Huang D, Wu Z, Tao H, Zhang S, Ma J, et al.
Ther Adv Med Oncol
. 2020 May;
12:1758835920922033.
PMID: 32426052
Background: Cutaneous adverse events (AEs) have been positively associated with immune checkpoint inhibitor (ICI) efficacy in patients with melanoma, but little is known regarding the association between checkpoint inhibitor pneumonitis...
10.
Huang D, Zhang F, Tao H, Zhang S, Ma J, Wang J, et al.
Target Oncol
. 2020 Feb;
15(1):93-100.
PMID: 32052340
Background: Immunotherapy based on programmed cell death protein 1 (PD-1)/programmed death-ligand 1 (PD-L1) inhibitors has revolutionized the treatment of non-small cell lung cancer (NSCLC). Patients with high PD-L1 expression or...